

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Investigating the effect of vitamin B1 oral tablets on the post covid-19 syndrome in comparison with the control group

#### Protocol summary

##### Study aim

Investigating the effect of vitamin B1 on the symptoms of post covid-19 syndrome

##### Design

A clinical trial with a control group, with a parallel group, randomized on 60 patients, rand function of Excel software was used for randomization.

##### Settings and conduct

60 patients of Labafinejad Hospital who are eligible entered the study and were divided into two groups of 30 people, the treatment group and the control group.

##### Participants/Inclusion and exclusion criteria

A patient who is eligible to enter the study (patients who have recovered from the disease of Covid-19, but their symptoms still persist more than usual, after three weeks of the onset of the symptoms of Covid-19, they also have symptoms such as fatigue, sleep disorders, decreased sense of taste and smell , etc.) Criteria for not entering the study: pregnant women, patients who use antipsychotic drugs, and patients with immunodeficiency

##### Intervention groups

Control group receives only supportive therapy (vitamin C, Famotidine, and Zinc) daily for 8 weeks. Intervention group receives vitamin B1 tablet (600 mg) daily for 8 weeks, in addition to the supportive therapy.

##### Main outcome variables

Sleep quality, Hair loss, Skin rashes, Dyspnea

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20221229056979N1**

Registration date: **2023-05-31, 1402/03/10**

Registration timing: **retrospective**

Last update: **2023-05-31, 1402/03/10**

Update count: **0**

##### Registration date

2023-05-31, 1402/03/10

##### Registrant information

###### Name

Elmira Mahmoudi Chalmiani

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 11 4203 0898

###### Email address

dr.elmira\_1991@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-03-21, 1401/01/01

##### Expected recruitment end date

2023-03-21, 1402/01/01

##### Actual recruitment start date

2022-03-21, 1401/01/01

##### Actual recruitment end date

2023-03-21, 1402/01/01

##### Trial completion date

2023-06-21, 1402/03/31

##### Scientific title

Investigating the effect of vitamin B1 oral tablets on the post covid-19 syndrome in comparison with the control group

##### Public title

Investigating the effect of vitamin B1 oral tablets on the post covid-19 syndrome

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

**Inclusion criteria:**

All Patients who have recovered from covid 19 but after three weeks the symptoms of post covid 19 syndrome remain

**Exclusion criteria:**

Pregnancy Immune deficiency patients Patients who use antipsychotic drugs

**Age**

From **15 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **60**

Actual sample size reached: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

First, 60 patients who are eligible to enter the study (patients who have recovered from the disease of covid-19, but their symptoms are still more than usual, after three weeks of the onset of symptoms of covid-19, have symptoms such as fatigue, sleep disorders, loss of sense of taste and smell, chest pain, cough, joint pain, hair loss, skin rashes, etc.) are at the time of admission background information including sex, age, clinical and drug records, disease manifestations and laboratory findings as well as symptoms Vitality and severity of the disease, history of hospitalization and receiving corticosteroids will be collected from the patients and recorded in the study checklist. Then for the patients of the treatment group (30 people) who will be randomly selected.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description**

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

Ethics Committee of Shahid Beheshti University of Medical Sciences

**Street address**

School of medicine of Shahid Beheshti University of medical sciences, Koodakyar Ave., Daneshjoo Blvd., Yaman St., Chamran highway.

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Approval date**

2021-08-10, 1400/05/19

**Ethics committee reference number**

IR.SBMU.MSP.REC.1400.286

**Health conditions studied**

**1**

**Description of health condition studied**

Post covid-19 syndrome

**ICD-10 code**

U07.1

**ICD-10 code description**

COVID-19, virus identified

**Primary outcomes**

**1**

**Description**

Sleep quality

**Timepoint**

Patients will be examined weekly during 9 weeks and the checklist will be completed for them.

**Method of measurement**

Questionnaire

**2**

**Description**

Hair loss

**Timepoint**

Patients will be examined weekly during 9 weeks and the checklist will be completed for them.

**Method of measurement**

Questionnaire

**3**

**Description**

Skin rashes

**Timepoint**

Patients will be examined weekly during 9 weeks and the checklist will be completed for them

**Method of measurement**

Questionnaire

**4**

**Description**

Dyspnea

**Timepoint**

Patients will be examined weekly during 9 weeks and the checklist will be completed for them

**Method of measurement**

Questionnaire

## Secondary outcomes

### 1

#### Description

Quality of life score

#### Timepoint

Patients will be examined weekly during 9 weeks and the checklist will be completed for them.

#### Method of measurement

Questionnaire

## Intervention groups

### 1

#### Description

Control group: Control group receives only supportive therapy including vitamin C, Famotidine, and Zinc (one tablet for each supplement) orally for 8 weeks.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: Intervention group receives vitamin B1 (600 mg daily for 8 weeks) in addition to supportive therapy (same as control group).

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Labafinezhad hospital

##### Full name of responsible person

Shabnam Tehrani

##### Street address

9th Boostan St., Pasdaran, Tehran

##### City

Tehran

##### Province

Tehran

##### Postal code

1666663111

##### Phone

+98 21 2360 2085

##### Email

dr.elmira\_1991@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences

#### Full name of responsible person

Dr. Afshin Zarghi

#### Street address

Shahid Beheshti University of Medical Sciences, No. 2, Arabi St., Yemen St., Chamran Highway, Tehran, Iran

#### City

Tehran

#### Province

Tehran

#### Postal code

1983969411

#### Phone

+98 21 2243 9780

#### Email

Mpajouhesh@sbmu.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shahid Beheshti University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences

##### Full name of responsible person

Shabnam tehrani

##### Position

Associate professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Infectious diseases

##### Street address

Zafar

##### City

Tehran

##### Province

Tehran

##### Postal code

1919753973

##### Phone

+98 21 2360 2084

##### Email

dr.elmira\_1991@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Shabnam tehrani

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Infectious diseases

**Street address**

Zafer

**City**

Tehran

**Province**

Tehran

**Postal code**

1919753973

**Phone**

+98 21 2360 2084

**Email**

dr.elmira\_1991@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Shabnam tehrani

**Position**

Associate professor

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Infectious diseases

**Street address**

Zafar

**City**

Tehran

**Province**

Tehran

**Postal code**

1919753973

**Phone**

+98 21 2360 2084

**Email**

dr.elmira\_1991@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

Part of the data, such as information related to the main outcome or similar, can be shared

**When the data will become available and for how long**

The beginning of the access period from 1402

**To whom data/document is available**

The data will be available only to researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

Data for clinical use will be available

**From where data/document is obtainable**

dr.elmira\_1991@yahoo.com

**What processes are involved for a request to access data/document**

After the request, the data will reach the requester within a week.

**Comments**